Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study

被引：9

作者：

Ferolla, P. ^{[1
,2
]}

Brizzi, M. P. ^{[3
]}

Meyer, T. ^{[4
,5
]}

Mansoor, W. ^{[6
]}

Mazieres, J. ^{[7
]}

Cao, C. D. ^{[8
]}

Lena, H. ^{[9
]}

Berruti, A. ^{[10
]}

Damiano, V. ^{[11
]}

Buikhuisen, W. ^{[12
]}

Stankovic, M. ^{[13
]}

Singh, N. ^{[14
]}

Chiodini, E. ^{[15
]}

Gislimberti, G. ^{[16
]}

Oberg, K. ^{[17
]}

Baudin, E. ^{[18
]}

机构：

[1] Umbria Reg Canc Network, Multidisciplinary NET Grp, Dept Med Oncol, Perugia, Italy

[2] Univ Perugia, Perugia, Italy

[3] Univ Turin, Dept Oncol, Turin, Italy

[4] Royal Free Hosp, Oncol, London, England

[5] UCL, London, England

[6] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England

[7] Hop Larrey, CHU Toulouse, Med Oncol, Toulouse, France

[8] CHRU Lille, Med Oncol, Lille, France

[9] Ctr Hosp Univ, Pneumol, Rennes, France

[10] Univ Brescia, Med Oncol, Brescia, Italy

[11] Azienda Osped Univ Policlin Federico II AOU Feder, Dept Dip Oncol, Endocr Mol Clin, Naples, Italy

[12] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands

[13] Novartis Pharma Serv Inc, Med Affairs, Novi Beograd, Serbia

[14] Cognizant Technol Solut, PLS Clin Project Mgt, Bombay, Maharashtra, India

[15] Parexel, Clin, Origgio, Italy

[16] OORE GMO, Gislimberti, Origgio, Italy

[17] Univ Uppsala Hosp, Dept Med Sci, Uppsala, Sweden

[18] Inst Gustave Roussy, Endocrinol, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw369.1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

416O

引用

页数：1